

# Pharmaids Pharmaceuticals Limited

PPL/BSE/2Q/0014/2019-20

Date: November 13<sup>th</sup>, 2019

To,  
The Corporate Relation Department  
The Stock Exchange,  
Mumbai, 1st Floor, Rotunda Building,  
Dalal Street, Mumbai-400001

BSE Security Code: 524572

**Sub:** Outcome of Board Meeting held on November 13<sup>th</sup>, 2019

We wish to inform you that the Board Directors of the Company, at their just concluded meeting, approved the Unaudited Financial Results of the Company for the Quarter and Half-year ended September 30<sup>th</sup>, 2019.

We are here with enclosing the unaudited financial results for Quarter and Half-year ended September 30<sup>th</sup>, 2019 along with the Limited Review Report issued by the statutory auditors of the Company.

Further, in compliance with Regulation 33 of Listing Regulations, the Board hereby declares/ certifies that the statutory auditors of the Company have submitted their Limited Review Report for the Quarter and half-year ended September 30<sup>th</sup>, 2019 with an unmodified and unqualified opinion.

The meeting commenced at 11.00 A.M. and concluded at 1.00 P.M.

This for your information and dissemination to the public.

Thanking you.

Yours faithfully

For Pharmaids Pharmaceuticals Limited

  
Authorized Signatory



CIN No. L52520TG1989PLC009679



# Pharmaids Pharmaceuticals Limited

## Statement of Profit and Loss account for the Quarter and Half year ended 30th September 2019

(Rs in Lacs)

	Particulars	Quarter Ended			Six Month Ended		Year ended
		Sept 30, 2019	June 30, 2019	Sept 30, 2018	Sept 30, 2019	Sept 30, 2018	
1	Revenue	-	-	-	-	-	48.10
2	Other Income	-	-	0.25	-	0.26	0.52
3	<b>Total Income</b>	-	-	0.25	-	0.26	48.62
4	<b>Expenses</b>						
	a) Cost of Material Consumed	-	-	-	-	-	-
	b) Purchase of Stock in Trade	-	-	-	-	-	35.62
	c) Changes in Inventories of Stock-in-Trade, Work in Progress and Finished Goods	-	-	-	-	-	-
	d) Employee Benefit Expenses	0.55	0.96	1.33	1.51	2.19	2.83
	e) Finance Cost	-	0.08	0.11	0.08	0.11	0.05
	f) Depreciation	0.04	0.04	0.02	0.08	0.04	0.14
	g) Other Expenses	5.38	5.78	7.84	11.16	10.56	24.75
	<b>Total Expenses</b>	5.97	6.86	9.30	12.83	12.90	63.39
5	Profit/loss before Exceptional item	(5.97)	(6.86)	(9.05)	(12.83)	(12.64)	(14.77)
6	Exceptional Items	-	-	-	-	-	-
7	Profit/(loss) before tax	(5.97)	(6.86)	(9.05)	(12.83)	(12.64)	(14.77)
8	Tax expense:						
	(1) Current tax Adj. of earlier year	-	-	-	-	-	-
	(2) Deferred tax	-	-	-	-	-	-
9	Profit (Loss) for the period from continuing operations	(5.97)	(6.86)	(9.05)	(12.83)	(12.64)	(14.77)
10	Profit/(loss) from discontinued operations	-	-	-	-	-	(3.70)
11	Tax expense of discontinued operations	-	-	-	-	-	-
12	Profit/(loss) from Discontinued operations (after tax)	(5.97)	(6.86)	(9.05)	(12.83)	(12.64)	(18.47)
13	Profit/(loss) for the period						
14	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
15	Total Comprehensive Income for the period (Comprising Profit (Loss) and Other Comprehensive Income for the period)	-	-	-	-	-	-
16	Earnings per equity share (for continuing operation):	(5.97)	(6.86)	(9.05)	(12.83)	(12.64)	(18.47)
	(1) Basic	(0.18)	(0.20)	(0.27)	(0.38)	(0.37)	(0.54)
	(2) Diluted	(0.18)	(0.20)	(0.27)	(0.38)	(0.37)	(0.54)

### Notes:

1.The above results have been reviewed by the Audit Committee and Approved by the Board of Directors of the Company at their meeting held on 13th November,2019.2.The Un-Audited Financial Results for the Quarter 2 and Half Year ended 30th September,2019 have been prepared and review by the Statutory Auditors in pursuance of Schedule III of Companies Act, 2013 3. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison. 4) The Company operates in a single segment and the results pertain to a single segment i.e. drug formulation only. 5.The Scheme of Amalgamation ("the Scheme") of Emergent Bio Naturals Limited("EBNL") with Pharmaids Pharmaceuticals Limited ("PPL")was approved by the Hon'ble National Company Law Tribunal vide its order dated September 27th ,2019("the NCLT Order").The Certified copy of the NCLT Order was filed with Registrar of Companies.

Place:Hyderabad

Date: 13.11.2019

For Pharmaids Pharmaceuticals Limited

*Chiranjeevi*  
Managing Director

CIN No. L52520TG1989PLC009679

Regd. Office : 4-4-211/212/3, Inder Bagh, Sultan Bazar, Hyderabad - 500 095, TELANGANA (INDIA)

Ph : 6559 9809, Tele Fax : 040-2756 2126, email : mailpharmaids@yahoo.co.in; Website : www.pharmaids.com

Unit : Survey No. 533, (V) Kondamadugu, (M) Bibi Nagar, District Naigonda (Telangana). Phone : +91-92470 58492

# Pharmaids Pharmaceuticals Limited

## STATEMENT OF ASSET AND LIABILITIES AS AT SEPTEMBER 30, 2019

(Rs in Lacs)

	Particulars	Note No.	Figures as at the end of 30.09.2019	Figures as at the end of 31.03.2019
	I	2	3	4
1	<b>ASSETS</b>			
	<b>Non-current assets</b>			
	(a) Property, Plant and Equipment		0.16	0.25
	(b) Capital work-in-progress		-	-
	(c) Investment Property		-	-
	(d) Goodwill		-	-
	(e) Other Intangible assets		-	-
	(f) Intangible assets under development		-	-
	(g) Biological Assets other than bearer plants		-	-
	(h) Financial Assets		-	-
	(i) Investments		-	-
	(ii) Trade receivables		-	-
	(iii) Loans		44.45	43.36
	(iv) Others (to be specified)		-	-
	(i) Deferred tax assets (net)		(3.68)	(3.68)
	(j) Other non-current assets		-	-
2	<b>Current assets</b>			
	(a) Inventories		-	-
	(b) Financial Assets		-	-
	(i) Investments		-	-
	(ii) Trade receivables		54.69	53.62
	(iii) Cash and cash equivalents		6.14	10.67
	(iv) Bank balances other than (iii) above		-	-
	(v) Loans		-	-
	(vi) Others (to be specified)		-	-
	(c) Current Tax Assets (Net)		-	-
	(d) Other current assets		-	-
	<b>Total Assets</b>		<b>101.76</b>	<b>104.22</b>
	<b>EQUITY AND LIABILITIES Equity</b>			
	(a) Equity Share capital		336.31	336.31
	(b) Other Equity		(263.42)	(250.58)
	<b>LIABILITIES</b>			
1	<b>Non-current liabilities</b>			
	(a) Financial Liabilities			
	(i) Borrowings		-	-
	(ii) Trade payables		-	-
	(iii) Other financial liabilities (other than those specified in		-	-
	(b) Provisions		-	-
	(c) Deferred tax liabilities (Net)		-	-
	(d) Other non-current liabilities		-	-
2	<b>Current liabilities</b>			
	(a) Financial Liabilities			
	(i) Borrowings		-	-
	(ii) Trade payables		24.15	15.96
	(iii) Other financial liabilities (other than those specified in		-	-
	(b) Other current liabilities		4.72	2.53
	(c) Provisions		-	-
	(d) Current Tax Liabilities (Net)		-	-
	<b>Total Equity and Liabilities</b>		<b>101.76</b>	<b>104.22</b>

CIN No. L52520TG1989PLC009679

Regd. Office : 4-4-211/212/3, Inder Bagh, Sultan Bazar, Hyderabad

Ph : 6559 9809, Tele Fax : 040-2756 2126. email : mailpharmaids@yahoo.co.in

Managing Director

Unit : Survey No. 533, (V) Kondamadugu, (M) Bibi Nagar, District Nalgonda (Telangana). Phone : 58492

# Pharmaids Pharmaceuticals Limited

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2019			
	Particulars	Figures as at the end of 30.09.2019 (Unaudited)	Figures as at the end of 30.09.2018 (Unaudited)
<b>A</b>	<b>CASHFLOW FROM OPERATING ACTIVITIES:</b>		
	Net Profit before Tax	(12.84)	(12.64)
	Adjustment for:		
	Depreciation and Amortization	0.09	0.04
	Interest Charged	-	-
	Interest Income	-	-
	Dividend Income/Gain on sale of Investments	-	-
	Provision / write off for doubtful trade receivables	-	-
	Deferred Tax	-	-
	<b>Operating Profit before change in working capital</b>	<b>(12.76)</b>	<b>(12.60)</b>
	<b>Working capital changes:</b>		
	Changes in Inventory	-	-
	Changes in Trade Receivables	(1.07)	(9.84)
	Change in Other Assets	-	8.42
	Changes in Trade payables	8.19	0.46
	Changes in Other liabilities	2.18	1.10
	Changes in Provisions	-	-
	<b>Cash generated from Operations</b>	<b>(3.46)</b>	<b>(12.46)</b>
	Direct tax paid (Net of Refunds)	-	-
	<b>Net Cash inflow from Operating Activities (A)</b>	<b>(3.46)</b>	<b>(12.46)</b>
<b>B</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES:</b>		
	Proceeds from Sale Asset	-	-
	Government assistance	-	-
	Interest received	-	-
	Dividend Income /Gain on Sale of Investments received	-	-
	Purchase of property, plant & equipments, intangible assets and Capital Advance	-	0.13
	Investment in Associate	-	-
	Intangible assets under development	-	-
	Long term loans and Advances	-	-
	<b>Net Cash inflow from Investing Activities (B)</b>	<b>-</b>	<b>0.13</b>
<b>C</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES:</b>		
	Proceeds from borrowings	(1.09)	-
	Net increase/ (decrease) in working capital demand loans	-	-
	Payment of lease liabilities	-	-
	Increase in Restricted Bank Balances other than Cash & Cash Equivalents	-	-
	Dividends paid (including distribution tax)	-	-
	Interest and other finance costs (including borrowing cost capitalised)	-	-
	<b>Net Cash inflow from Financing Activities (C)</b>	<b>(1.09)</b>	<b>-</b>
<b>I</b>	<b>Net (decrease)/increase in cash and cash equivalents (A+B+C)</b>	<b>(4.55)</b>	<b>(12.33)</b>
<b>II</b>	<b>a) Cash and Cash Equivalents at the beginning of the year</b>	<b>10.68</b>	<b>23.35</b>
	<b>b) Effect of Exchange difference on restatement of foreign currency cash and cash equivalents</b>	<b>-</b>	<b>-</b>
	<b>c) Effect of Fairvalue change of investment held for Trading</b>	<b>-</b>	<b>-</b>
<b>III</b>	<b>Cash and Cash Equivalents at the end of the year (I+II)</b>	<b>6.13</b>	<b>11.01</b>
<b>IV</b>	<b>Cash and Cash Equivalents at half year end</b>	<b>6.13</b>	<b>11.01</b>

For Pharmaids Pharmaceuticals Limited

*Charitabale*



9679

Regd. Office : 4-4-211/212/3, Inder Bagh, Sultan Bazar, Hyderabad - 500 095, TELANGANA (INDIA)  
Ph : 6559 9809, Tele Fax : 040-2756 2120 Email : pharmaids@yahoo.co.in Website : www.pharmaids.com

Unit : Survey No. 733, (V) Kondamadugu, (M) Bibi Nagar, District Nalgonda (Telangana). Phone : +91-92470 58492



# Chartered Accountants **PPKG & Co**

#5-8-352, 701, 7th Floor, Rainbow Park, IT Mall,  
Cyberabad, Hyderabad - 500 081  
Ph : +91-40-23205046, 23205047  
email : gird@ppkg.com • www.ppkg.com

## **INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS**

To  
The Board of Directors,  
Pharmaids Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited financial results of **PHARMAIDS PHARMACEUTICALS LIMITED** ("the Company") for the Quarter and Six Months Ended 30<sup>th</sup> September, 2019 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement

Place : Hyderabad

Date : 13th November, 2019

Udin no. - 19205140 AA AAKQ7443

**For PPKG & CO**  
Chartered Accountants  
FRN No. 009655S

*Girdhari Lal Toshniwal*  
**GIRDHARI LAL TOSHNIWAL**  
(Partner)

M. No. 205140  
UDIN:



**Detach**